Growth Hormone Deficiency Market

Growth Hormone Deficiency Market (Treatment Type: Therapeutic Treatment, Recombinant Human Growth Hormone, Human Pituitary Gland Extracts, and Surgery) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2034

Growth Hormone Deficiency Market Outlook 2034

  • The global industry was valued at US$ 4.3 Bn in 2023
  • It is expected to grow at a CAGR of 4.4% from 2024 to 2034 and reach US$ 7.0 Bn by the end of 2034

Analyst Viewpoint

Rise in incidence of growth hormone deficiencies is the factor basically responsible for the expansion of growth hormone deficiency market. Growth hormone deficiency is amongst the disorders characterized by inappropriate secretion of the growth hormone (GH) from anterior pituitary gland, which truncates the height of children. Besides, secretion of this hormone declines with the passage of age.

The companies operating in growth hormone deficiency market are collaborating with various research institutes to explore the incorporation of investigational oral therapy that is in analogy with human growth hormone in pediatric growth hormone deficiency. They are looking toward adopting this therapy in line with the research findings that state that it increases height velocity for the children.

Growth Hormone Deficiency Market Overview

Growth hormone deficiency, also called pituitary dwarfism, is referred to as a condition resulting out of insufficient quantities of growth hormone in body. Those suffering from this deficiency generally have an abnormally short stature.

There has been a persistent rise in public understanding regarding application of synthetic growth hormone therapy. This human growth hormone aids in stimulating reproduction, regeneration, and growth of the humans. Development of new-fangled recombinant human growth hormones is likely of contributing to growth hormone deficiency industry growth.

As per a research article published in the Intractable & Rare Diseases Research 2018 by Xiaoxiao Cui et al., Turner Syndrome (TS) us a relatively common kind of human chromosomal aberration occurring in 1 amongst 2,500 live female births. Majority of patients are found in China.

Attribute Detail
Market Drivers
  • Rise in Incidence of Growth Hormone Deficiencies
  • Increase in Geriatric Population

Growing Prevalence of Growth Hormone Deficiencies Propelling Demand for Growth Hormone Replacement

Growth hormone deficiency may be total (pituitary gland does not produce any growth hormone) or partial (pituitary gland produces insufficient quantity of growth hormone). It is likely to occur either at the time of infancy or later during childhood. Early detection as well as treatment can help such children in reaching a normal height.

Though growth hormone deficiency does not adversely affect the child’s intelligence, he/she may have an immature appearance as compared to the peers, along with a chubby body build, underdeveloped bridge of nose, and prominent forehead.

Growth hormone deficiency ends up affecting one in close to 4,000 to 10,000 people. It could be congenital (such as caused due to genetic mutation) or acquired post-birth owing to trauma, radiation therapy, surgery, or brain tumor.

Need to diagnose growth hormone deficiency on time is thus accelerating the growth hormone deficiency market opportunities.

Rise in Geriatric Population Driving Demand for Human Growth Hormone Treatment

Research states that secretion of growth hormones falls with aging. It further states that over 30% of the elderly population has circulating growth hormone levels below the normal range.

As per the National Institutes of Health, progressive decline of growth hormone secretion amounts to 15% for every decade post 30 years of age. It also mentions that integrated measurements of the daily growth hormone secretion states that this secretion is at its peak at puberty at close to 150 µg/Kg/day, then declines to around 25 µg/Kg/day by the age of 55.

As per the WHO, the percentage of population aged 60 and above will increase from 12% to 22% between 2015 and 2050.

Need to address the concerns pertaining to growth hormone insufficiency of the aging population is thus expanding the growth hormone deficiency market size.

Regional Analysis

Attribute Detail
Leading Region North America

As per the latest growth hormone deficiency market analysis, North America dominated the growth hormone therapy landscape and the scenario is expected to remain unchanged during the forecast period. This is attributed to conducive reimbursement policies laid down by the U.S., along with well-established healthcare infrastructure.

Additionally, growing awareness regarding hormonal deficiencies is expected to bolster the growth hormone deficiency market. For example, the International Coalition of Organizations Supporting Endocrine Patients (ICOSEP) celebrates the Children’s Growth Awareness Day for spreading awareness regarding early diagnosis as well as treatment of the growth hormone disorders.

Analysis of Key Players

The key players in the growth hormone deficiency market are launching new products and seeking speedy approvals to overpower the counterparts. For instance, in September 2020, Novo Nordisk received approval from the U.S. FDA for Sogroya (somapacitan). It is used for treating adults contracting growth hormone deficiency.

Novo Nordisk A/S, Pfizer Inc., Merck KGaA, Eli Lilly and Company, Novartis AG, F. Hoffmann-La Roche AG, Ipsen Pharma, Ferring Pharmaceuticals, Anhui Anke Biotechnology (Group) Co., Ltd., Zhongshan Sinobioway Hygene Biomedicine Co., Ltd., and Others are some of the key players covered in the growth hormone deficiency market report.

These companies have been profiled based on parameters such as company overview, business strategies, financial overview, product portfolio, and business segments.

Competitive Landscape of the Growth Hormone Deficiency Market

  • In February 2021, Pfizer Inc. started with a Phase III clinical trial with the objective of evaluating safety and efficacy of somatropin in a group of Japanese participants suffering from Prader-Willi Syndrome (PWS).
  • In October 2020, Erasmus Medical Center started with a Phase III clinical trial in collaboration with Pfizer, Prader-Willi Fonds, and Foundation for Prader-Willi Research for assessing effect of genotropin (growth hormone treatment) on psychosocial and physical health in the adults aged 30 or older and suffering from Prader-Willi syndrome.

Global Growth Hormone Deficiency Market Snapshot

Attribute Detail
Market Size in 2023 US$ 4.3 Bn
Market Forecast (Value) in 2034 US$ 7.0 Bn
Growth Rate (CAGR) 4.4%
Forecast Period 2024-2034
Historical Data Available for 2020-2022
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2023)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Treatment Type
    • Therapeutic Treatment
      • Norditropin
      • Genotropin
      • Humatrope
      • Saizen
      • Others (Omnitrope, etc.)
    • Recombinant Human Growth Hormone
    • Human Pituitary Gland Extracts
    • Surgery
  • Disease Indication
    • Pediatric Growth Hormone Deficiency
    • Idiopathic Short Stature
    • Small for Gestational Age
    • Turner Syndrome
    • Adult Growth Hormone Deficiency
    • Others (Prader-Willi Syndrome, etc.)
  • Route of Administration
    • Subcutaneous
    • Intramuscular
    • Intravenous
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Brazil
  • Mexico
  • South Africa
  • GCC
Companies Profiled
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Merck KGaA
  • Eli Lilly and Company
  • Novartis AG
  • F. Hoffmann-La Roche AG
  • Ipsen Pharma
  • Ferring Pharmaceuticals
  • Anhui Anke Biotechnology (Group) Co., Ltd.
  • Zhongshan Sinobioway Hygene Biomedicine Co., Ltd.
Customization Scope Available Upon Request
Pricing Available Upon Request

Frequently Asked Questions

How big was the global growth hormone deficiency market in 2023?

It was valued at US$ 4.3 Bn in 2023

How is the growth hormone deficiency business expected to grow during the forecast period?

It is projected to grow at a CAGR of 4.4% from 2024 to 2034

What are the key factors driving the demand for growth hormone deficiency?

Growing prevalence of growth hormone deficiencies and rise in geriatric population

Which growth hormone deficiency distribution channel segment held the largest share in 2023?

Hospital pharmacies segment accounted for the largest share in 2023

Which region dominated the global growth hormone deficiency landscape in 2023?

North America was the dominant region in 2023

Who are the key growth hormone deficiency industry key players?

Novo Nordisk A/S, Pfizer Inc., Merck KGaA, Eli Lilly and Company, Novartis AG, F. Hoffmann-La Roche AG, Ipsen Pharma, Ferring Pharmaceuticals, Anhui Anke Biotechnology (Group) Co., Ltd., Zhongshan Sinobioway Hygene Biomedicine Co., Ltd., and Others

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Growth Hormone Deficiency Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Product Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Growth Hormone Deficiency Market Analysis and Forecast, 2020-2034

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. Key Product/Brand Analysis

        5.3. Key Mergers & Acquisitions

        5.4. COVID-19 Pandemic Impact on Industry

    6. Global Growth Hormone Deficiency Market Analysis and Forecast, by Treatment Type

        6.1. Introduction and Definitions

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Treatment Type, 2020-2034

            6.3.1. Therapeutic Treatment

                6.3.1.1. Norditropin

                6.3.1.2. Genotropin

                6.3.1.3. Humatrope

                6.3.1.4. Saizen

                6.3.1.5. Others (Omnitrope, etc.)

            6.3.2. Recombinant Human Growth Hormone

            6.3.3. Human Pituitary Gland Extracts

            6.3.4. Surgery

        6.4. Market Attractiveness, by Treatment Type

    7. Global Growth Hormone Deficiency Market Analysis and Forecast, by Disease Indication

        7.1. Introduction and Definitions

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Disease Indication, 2020-2034

            7.3.1. Pediatric Growth Hormone Deficiency

            7.3.2. Idiopathic Short Stature

            7.3.3. Small for Gestational Age

            7.3.4. Turner Syndrome

            7.3.5. Adult Growth Hormone Deficiency

            7.3.6. Others (Prader-Willi Syndrome, etc.)

            7.3.7. 7.4 Market Attractiveness, by Disease Indication

    8. Global Growth Hormone Deficiency Market Analysis and Forecast, by Route of Administration

        8.1. Introduction and Definitions

        8.2. Key Findings/Developments

        8.3. Market Value Forecast, by Route of Administration, 2020-2034

            8.3.1. Subcutaneous

            8.3.2. Intramuscular

            8.3.3. Intravenous

        8.4. Market Attractiveness, by Route of Administration

    9. Global Growth Hormone Deficiency Market Analysis and Forecast, by Distribution Channel

        9.1. Introduction and Definitions

        9.2. Key Findings/Developments

        9.3. Market Value Forecast, by Distribution Channel, 2020-2034

            9.3.1. Hospital Pharmacies

            9.3.2. Retail Pharmacies

            9.3.3. Online Pharmacies

        9.4. Market Attractiveness, by Distribution Channel

    10. Global Growth Hormone Deficiency Market Analysis and Forecast, by Region

        10.1. Key Findings

        10.2. Market Value Forecast, by Region, 2020-2034

            10.2.1. North America

            10.2.2. Europe

            10.2.3. Asia Pacific

            10.2.4. Latin America

            10.2.5. Middle East & Africa

        10.3. Market Attractiveness, by Region

    11. North America Growth Hormone Deficiency Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Treatment Type, 2020-2034

            11.2.1. Therapeutic Treatment

                11.2.1.1. Norditropin

                11.2.1.2. Genotropin

                11.2.1.3. Humatrope

                11.2.1.4. Saizen

                11.2.1.5. Others (Omnitrope, etc.)

            11.2.2. Recombinant Human Growth Hormone

            11.2.3. Human Pituitary Gland Extracts

            11.2.4. Surgery

        11.3. Market Attractiveness, by Treatment Type

        11.4. Market Value Forecast, by Disease Indication, 2020-2034

            11.4.1. Pediatric Growth Hormone Deficiency

            11.4.2. Idiopathic Short Stature

            11.4.3. Small for Gestational Age

            11.4.4. Turner Syndrome

            11.4.5. Adult Growth Hormone Deficiency

            11.4.6. Others (Prader-Willi Syndrome, etc.)

        11.5. Market Attractiveness, by Disease Indication

        11.6. Market Value Forecast, by Route of Administration, 2020-2034

            11.6.1. Subcutaneous

            11.6.2. Intramuscular

            11.6.3. Intravenous

        11.7. Market Attractiveness, by Route of Administration

        11.8. Market Value Forecast, by Distribution Channel, 2020-2034

            11.8.1. Hospital Pharmacies

            11.8.2. Retail Pharmacies

            11.8.3. Online Pharmacies

        11.9. Market Attractiveness, by Distribution Channel

        11.10. Market Value Forecast, by Country/Sub-region, 2020-2034

            11.10.1. U.S.

            11.10.2. Canada

        11.11. Market Attractiveness Analysis

            11.11.1. By Treatment Type

            11.11.2. By Disease Indication

            11.11.3. By Route of Administration

            11.11.4. By Distribution Channel

            11.11.5. By Country

    12. Europe Growth Hormone Deficiency Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Treatment Type, 2020-2034

            12.2.1. Therapeutic Treatment

                12.2.1.1. Norditropin

                12.2.1.2. Genotropin

                12.2.1.3. Humatrope

                12.2.1.4. Saizen

                12.2.1.5. Others (Omnitrope, etc.)

            12.2.2. Recombinant Human Growth Hormone

            12.2.3. Human Pituitary Gland Extracts

            12.2.4. Surgery

        12.3. Market Attractiveness, by Treatment Type

        12.4. Market Value Forecast, by Disease Indication, 2020-2034

            12.4.1. Pediatric Growth Hormone Deficiency

            12.4.2. Idiopathic Short Stature

            12.4.3. Small for Gestational Age

            12.4.4. Turner Syndrome

            12.4.5. Adult Growth Hormone Deficiency

            12.4.6. Others (Prader-Willi Syndrome, etc.)

        12.5. Market Attractiveness, by Disease Indication

        12.6. Market Value Forecast, by Route of Administration, 2020-2034

            12.6.1. Subcutaneous

            12.6.2. Intramuscular

            12.6.3. Intravenous

        12.7. Market Attractiveness, by Route of Administration

        12.8. Market Value Forecast, by Distribution Channel, 2020-2034

            12.8.1. Hospital Pharmacies

            12.8.2. Retail Pharmacies

            12.8.3. Online Pharmacies

        12.9. Market Attractiveness, by Distribution Channel

        12.10. Market Value Forecast, by Country/Sub-region, 2020-2034

            12.10.1. Germany

            12.10.2. U.K.

            12.10.3. France

            12.10.4. Italy

            12.10.5. Spain

            12.10.6. Rest of Europe

        12.11. Market Attractiveness Analysis

            12.11.1. By Treatment Type

            12.11.2. By Disease Indication

            12.11.3. By Route of Administration

            12.11.4. By Distribution Channel

            12.11.5. By Country/Sub-region

    13. Asia Pacific Growth Hormone Deficiency Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Treatment Type, 2020-2034

            13.2.1. Therapeutic Treatment

                13.2.1.1. Norditropin

                13.2.1.2. Genotropin

                13.2.1.3. Humatrope

                13.2.1.4. Saizen

                13.2.1.5. Others (Omnitrope, etc.)

            13.2.2. Recombinant Human Growth Hormone

            13.2.3. Human Pituitary Gland Extracts

            13.2.4. Surgery

        13.3. Market Attractiveness, by Treatment Type

        13.4. Market Value Forecast, by Disease Indication, 2020-2034

            13.4.1. Pediatric Growth Hormone Deficiency

            13.4.2. Idiopathic Short Stature

            13.4.3. Small for Gestational Age

            13.4.4. Turner Syndrome

            13.4.5. Adult Growth Hormone Deficiency

            13.4.6. Others (Prader-Willi Syndrome, etc.)

        13.5. Market Attractiveness, by Disease Indication

        13.6. Market Value Forecast, by Route of Administration, 2020-2034

            13.6.1. Subcutaneous

            13.6.2. Intramuscular

            13.6.3. Intravenous

        13.7. Market Attractiveness, by Route of Administration

        13.8. Market Value Forecast, by Distribution Channel, 2020-2034

            13.8.1. Hospital Pharmacies

            13.8.2. Retail Pharmacies

            13.8.3. Online Pharmacies

        13.9. Market Attractiveness, by Distribution Channel

        13.10. Market Value Forecast, by Country/Sub-region, 2020-2034

            13.10.1. China

            13.10.2. Japan

            13.10.3. India

            13.10.4. Australia & New Zealand

            13.10.5. Rest of Asia Pacific

        13.11. Market Attractiveness Analysis

            13.11.1. By Treatment Type

            13.11.2. By Disease Indication

            13.11.3. By Route of Administration

            13.11.4. By Distribution Channel

            13.11.5. By Country/Sub-region

    14. Latin America Growth Hormone Deficiency Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast, by Treatment Type, 2020-2034

            14.2.1. Therapeutic Treatment

                14.2.1.1. Norditropin

                14.2.1.2. Genotropin

                14.2.1.3. Humatrope

                14.2.1.4. Saizen

                14.2.1.5. Others (Omnitrope, etc.)

            14.2.2. Recombinant Human Growth Hormone

            14.2.3. Human Pituitary Gland Extracts

            14.2.4. Surgery

        14.3. Market Attractiveness, by Treatment Type

        14.4. Market Value Forecast, by Disease Indication, 2020-2034

            14.4.1. Pediatric Growth Hormone Deficiency

            14.4.2. Idiopathic Short Stature

            14.4.3. Small for Gestational Age

            14.4.4. Turner Syndrome

            14.4.5. Adult Growth Hormone Deficiency

            14.4.6. Others (Prader-Willi Syndrome, etc.)

        14.5. Market Attractiveness, by Disease Indication

        14.6. Market Value Forecast, by Route of Administration, 2020-2034

            14.6.1. Subcutaneous

            14.6.2. Intramuscular

            14.6.3. Intravenous

        14.7. Market Attractiveness, by Route of Administration

        14.8. Market Value Forecast, by Distribution Channel, 2020-2034

            14.8.1. Hospital Pharmacies

            14.8.2. Retail Pharmacies

            14.8.3. Online Pharmacies

        14.9. Market Attractiveness, by Distribution Channel

        14.10. Market Value Forecast, by Country/Sub-region, 2020-2034

            14.10.1. Brazil

            14.10.2. Mexico

            14.10.3. Rest of Latin America

        14.11. Market Attractiveness Analysis

            14.11.1. By Treatment Type

            14.11.2. By Disease Indication

            14.11.3. By Route of Administration

            14.11.4. By Distribution Channel

            14.11.5. By Country/Sub-region

    15. Middle East & Africa Growth Hormone Deficiency Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast, by Treatment Type, 2020-2034

            15.2.1. Therapeutic Treatment

                15.2.1.1. Norditropin

                15.2.1.2. Genotropin

                15.2.1.3. Humatrope

                15.2.1.4. Saizen

                15.2.1.5. Others (Omnitrope, etc.)

            15.2.2. Recombinant Human Growth Hormone

            15.2.3. Human Pituitary Gland Extracts

            15.2.4. Surgery

        15.3. Market Attractiveness, by Treatment Type

        15.4. Market Value Forecast, by Disease Indication, 2020-2034

            15.4.1. Pediatric Growth Hormone Deficiency

            15.4.2. Idiopathic Short Stature

            15.4.3. Small for Gestational Age

            15.4.4. Turner Syndrome

            15.4.5. Adult Growth Hormone Deficiency

            15.4.6. Others (Prader-Willi Syndrome, etc.)

        15.5. Market Attractiveness, by Disease Indication

        15.6. Market Value Forecast, by Route of Administration, 2020-2034

            15.6.1. Subcutaneous

            15.6.2. Intramuscular

            15.6.3. Intravenous

        15.7. Market Attractiveness, by Route of Administration

        15.8. Market Value Forecast, by Distribution Channel, 2020-2034

            15.8.1. Hospital Pharmacies

            15.8.2. Retail Pharmacies

            15.8.3. Online Pharmacies

        15.9. Market Attractiveness, by Distribution Channel

        15.10. Market Value Forecast, by Country/Sub-region, 2020-2034

            15.10.1. GCC Countries

            15.10.2. South Africa

            15.10.3. Rest of Middle East & Africa

        15.11. Market Attractiveness Analysis

            15.11.1. By Treatment Type

            15.11.2. By Disease Indication

            15.11.3. By Route of Administration

            15.11.4. By Distribution Channel

            15.11.5. By Country/Sub-region

    16. Competition Landscape

        16.1. Market Player – Competition Matrix (By Tier and Size of Companies)

        16.2. Market Share Analysis, by Company (2023)

        16.3. Company Profiles

            16.3.1. Novo Nordisk A/S

                16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.1.2. Product Portfolio

                16.3.1.3. Financial Overview

                16.3.1.4. SWOT Analysis

                16.3.1.5. Strategic Overview

            16.3.2. Pfizer Inc.

                16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.2.2. Product Portfolio

                16.3.2.3. Financial Overview

                16.3.2.4. SWOT Analysis

                16.3.2.5. Strategic Overview

            16.3.3. Merck KGaA

                16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.3.2. Product Portfolio

                16.3.3.3. Financial Overview

                16.3.3.4. SWOT Analysis

                16.3.3.5. Strategic Overview

            16.3.4. Eli Lilly and Company

                16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.4.2. Product Portfolio

                16.3.4.3. Financial Overview

                16.3.4.4. SWOT Analysis

                16.3.4.5. Strategic Overview

            16.3.5. Novartis AG

                16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.5.2. Product Portfolio

                16.3.5.3. Financial Overview

                16.3.5.4. SWOT Analysis

                16.3.5.5. Strategic Overview

            16.3.6. F. Hoffmann-La Roche AG

                16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.6.2. Product Portfolio

                16.3.6.3. Financial Overview

                16.3.6.4. SWOT Analysis

                16.3.6.5. Strategic Overview

            16.3.7. Ipsen Pharma

                16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.7.2. Product Portfolio

                16.3.7.3. Financial Overview

                16.3.7.4. SWOT Analysis

                16.3.7.5. Strategic Overview

            16.3.8. Ferring Pharmaceuticals

                16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.8.2. Product Portfolio

                16.3.8.3. Financial Overview

                16.3.8.4. SWOT Analysis

                16.3.8.5. Strategic Overview

            16.3.9. Anhui Anke Biotechnology (Group) Co., Ltd.

                16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.9.2. Product Portfolio

                16.3.9.3. Financial Overview

                16.3.9.4. SWOT Analysis

                16.3.9.5. Strategic Overview

            16.3.10. Zhongshan Sinobioway Hygene Biomedicine Co., Ltd.

                16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.10.2. Product Portfolio

                16.3.10.3. Financial Overview

                16.3.10.4. SWOT Analysis

                16.3.10.5. Strategic Overview

            16.3.11. Others

                16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.11.2. Product Portfolio

                16.3.11.3. Financial Overview

                16.3.11.4. SWOT Analysis

                16.3.11.5. Strategic Overview

    List of Tables

    Table 01: Global Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034

    Table 02: Global Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034

    Table 03: Global Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

    Table 04: Global Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034

    Table 05: Global Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Region, 2020-2034

    Table 06: North America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Country, 2020-2034

    Table 07: North America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034

    Table 08: North America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034

    Table 9: North America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034

    Table 10: North America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

    Table 11: Europe Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

    Table 12: Europe Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034

    Table 13: Europe Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034

    Table 14: Europe Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034

    Table 15: Europe Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

    Table 16: Asia Pacific Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

    Table 17: Asia Pacific Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034

    Table 18: Asia Pacific Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034

    Table 19: Asia Pacific Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034

    Table 20: Asia Pacific Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

    Table 21: Latin America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

    Table 22: Latin America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034

    Table 23: Latin America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034

    Table 24: Latin America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034

    Table 25: Latin America Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

    Table 26: Middle East & Africa Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Country/Sub-region, 2020-2034

    Table 27: Middle East & Africa Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Treatment Type, 2020-2034

    Table 28: Middle East & Africa Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Disease Indication, 2020-2034

    Table 29: Middle East & Africa Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Route of Administration, 2020-2034

    Table 30: Middle East & Africa Growth Hormone Deficiency Market Size (US$ Bn) Forecast, by Distribution Channel, 2020-2034

    List of Figures

    Figure 01: Global Growth Hormone Deficiency Market Size (US$ Bn), by Region, 2023 and 2034

    Figure 02: Global Growth Hormone Deficiency Market Revenue (US$ Bn), by Treatment Type, 2023

    Figure 03: Global Growth Hormone Deficiency Market Value Share, by Treatment Type, 2023

    Figure 04: Global Growth Hormone Deficiency Market Revenue (US$ Bn), by Disease Indication, 2023

    Figure 05: Global Growth Hormone Deficiency Market Value Share, by Disease Indication, 2023

    Figure 06: Global Growth Hormone Deficiency Market Revenue (US$ Bn), by Route of Administration, 2023

    Figure 07: Global Growth Hormone Deficiency Market Value Share, by Route of Administration, 2023

    Figure 08: Global Growth Hormone Deficiency Market Revenue (US$ Bn), by Distribution Channel, 2023

    Figure 09: Global Growth Hormone Deficiency Market Value Share, by Distribution Channel, 2023

    Figure 10: Global Growth Hormone Deficiency Market Value Share, by Region, 2023

    Figure 11: Global Growth Hormone Deficiency Market Value (US$ Bn) Forecast, 2020-2034

    Figure 12: Global Growth Hormone Deficiency Market Value Share Analysis, by Treatment Type, 2023 and 2034

    Figure 13: Global Growth Hormone Deficiency Market Attractiveness Analysis, by Treatment Type, 2024-2034

    Figure 14: Global Growth Hormone Deficiency Market Value Share Analysis, by Disease Indication, 2023 and 2034

    Figure 15: Global Growth Hormone Deficiency Market Attractiveness Analysis, by Disease Indication, 2024-2034

    Figure 16: Global Growth Hormone Deficiency Market Value Share Analysis, by Route of Administration, 2023 and 2034

    Figure 17: Global Growth Hormone Deficiency Market Attractiveness Analysis, by Route of Administration, 2024-2034

    Figure 18: Global Growth Hormone Deficiency Market Revenue (US$ Bn), by Distribution Channel, 2023

    Figure 19: Global Growth Hormone Deficiency Market Value Share, by Distribution Channel, 2023

    Figure 20: Global Growth Hormone Deficiency Market Value Share Analysis, by Region, 2023 and 2034

    Figure 21: Global Growth Hormone Deficiency Market Attractiveness Analysis, by Region, 2024-2034

    Figure 22: North America Growth Hormone Deficiency Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

    Figure 23: North America Growth Hormone Deficiency Market Attractiveness Analysis, by Country, 2024-2034

    Figure 24: North America Growth Hormone Deficiency Market Value Share Analysis, by Country, 2023 and 2034

    Figure 25: North America Growth Hormone Deficiency Market Value Share Analysis, by Treatment Type, 2023 and 2034

    Figure 26: North America Growth Hormone Deficiency Market Value Share Analysis, by Disease Indication, 2023 and 2034

    Figure 27: North America Growth Hormone Deficiency Market Value Share Analysis, by Route of Administration, 2023 and 2034

    Figure 28: North America Growth Hormone Deficiency Market Value Share Analysis, by Distribution Channel, 2023 and 2034

    Figure 29: North America Growth Hormone Deficiency Market Attractiveness Analysis, by Treatment Type, 2024-2034

    Figure 30: North America Growth Hormone Deficiency Market Attractiveness Analysis, by Disease Indication, 2024-2034

    Figure 31: North America Growth Hormone Deficiency Market Attractiveness Analysis, by Route of Administration, 2024-2034

    Figure 32: North America Growth Hormone Deficiency Market Attractiveness Analysis, by Distribution Channel, 2024-2034

    Figure 33: Europe Growth Hormone Deficiency Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

    Figure 34: Europe Growth Hormone Deficiency Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

    Figure 35: Europe Growth Hormone Deficiency Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

    Figure 36: Europe Growth Hormone Deficiency Market Value Share Analysis, by Treatment Type, 2023 and 2034

    Figure 37: Europe Growth Hormone Deficiency Market Value Share Analysis, by Disease Indication, 2023 and 2034

    Figure 38: Europe Growth Hormone Deficiency Market Value Share Analysis, by Route of Administration, 2023 and 2034

    Figure 39: Europe Growth Hormone Deficiency Market Value Share Analysis, by Distribution Channel, 2023 and 2034

    Figure 40: Europe Growth Hormone Deficiency Market Attractiveness Analysis, by Treatment Type, 2024-2034

    Figure 41: Europe Growth Hormone Deficiency Market Attractiveness Analysis, by Disease Indication, 2024-2034

    Figure 42: Europe Growth Hormone Deficiency Market Attractiveness Analysis, by Route of Administration, 2024-2034

    Figure 43: Europe Growth Hormone Deficiency Market Attractiveness Analysis, by Distribution Channel, 2024-2034

    Figure 44: Asia Pacific Growth Hormone Deficiency Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

    Figure 45: Asia Pacific Growth Hormone Deficiency Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

    Figure 46: Asia Pacific Growth Hormone Deficiency Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

    Figure 47: Asia Pacific Growth Hormone Deficiency Market Value Share Analysis, by Treatment Type, 2023 and 2034

    Figure 48: Asia Pacific Growth Hormone Deficiency Market Value Share Analysis, by Disease Indication, 2023 and 2034

    Figure 49: Asia Pacific Growth Hormone Deficiency Market Value Share Analysis, by Route of Administration, 2023 and 2034

    Figure 50: Asia Pacific Growth Hormone Deficiency Market Value Share Analysis, by Distribution Channel, 2023 and 2034

    Figure 51: Asia Pacific Growth Hormone Deficiency Market Attractiveness Analysis, by Treatment Type, 2024-2034

    Figure 52: Asia Pacific Growth Hormone Deficiency Market Attractiveness Analysis, by Disease Indication, 2024-2034

    Figure 53: Asia Pacific Growth Hormone Deficiency Market Attractiveness Analysis, by Route of Administration, 2024-2034

    Figure 54: Asia Pacific Growth Hormone Deficiency Market Attractiveness Analysis, by Distribution Channel, 2023–2034

    Figure 55: Latin America Growth Hormone Deficiency Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

    Figure 56: Latin America Growth Hormone Deficiency Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

    Figure 57: Latin America Growth Hormone Deficiency Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

    Figure 58: Latin America Growth Hormone Deficiency Market Value Share Analysis, by Treatment Type, 2023 and 2034

    Figure 59: Latin America Growth Hormone Deficiency Market Value Share Analysis, by Disease Indication, 2023 and 2034

    Figure 60: Latin America Growth Hormone Deficiency Market Value Share Analysis, by Route of Administration, 2023 and 2034

    Figure 61: Latin America Growth Hormone Deficiency Market Value Share Analysis, by Distribution Channel, 2023 and 2034

    Figure 62: Latin America Growth Hormone Deficiency Market Attractiveness Analysis, by Treatment Type, 2024-2034

    Figure 63: Latin America Growth Hormone Deficiency Market Attractiveness Analysis, by Disease Indication, 2024-2034

    Figure 64: Latin America Growth Hormone Deficiency Market Attractiveness Analysis, by Route of Administration, 2024-2034

    Figure 65: Latin America Growth Hormone Deficiency Market Attractiveness Analysis, by Distribution Channel, 2024-2034

    Figure 66: Middle East & Africa Growth Hormone Deficiency Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2020-2034

    Figure 67: Middle East & Africa Growth Hormone Deficiency Market Attractiveness Analysis, by Country/Sub-region, 2024-2034

    Figure 68: Middle East & Africa Growth Hormone Deficiency Market Value Share Analysis, by Country/Sub-region, 2023 and 2034

    Figure 69: Middle East & Africa Growth Hormone Deficiency Market Value Share Analysis, by Treatment Type, 2023 and 2034

    Figure 70: Middle East & Africa Growth Hormone Deficiency Market Value Share Analysis, by Disease Indication, 2023 and 2034

    Figure 71: Middle East & Africa Growth Hormone Deficiency Market Value Share Analysis, by Route of Administration, 2023 and 2034

    Figure 72: Middle East & Africa Growth Hormone Deficiency Market Value Share Analysis, by Distribution Channel, 2023 and 2034

    Figure 73: Middle East & Africa Growth Hormone Deficiency Market Attractiveness Analysis, by Treatment Type, 2024-2034

    Figure 74: Middle East & Africa Growth Hormone Deficiency Market Attractiveness Analysis, by Disease Indication, 2024-2034

    Figure 75: Middle East & Africa Growth Hormone Deficiency Market Attractiveness Analysis, by Route of Administration, 2024-2034

    Figure 76: Middle East & Africa Growth Hormone Deficiency Market Attractiveness Analysis, by Distribution Channel, 2024-2034

Copyright © Transparency Market Research, Inc. All Rights reserved